


## CLAIMS

What is claimed is:

1. **(currently amended)** A compound of Formula (I)



(I)

wherein

X is carbon and Y is nitrogen or X is nitrogen and Y is carbon;

R<sup>1</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, halogen, or cyano;

R<sup>2</sup> and R<sup>3</sup> are each independently (CH<sub>2</sub>)<sub>n</sub>-aryl or (CH<sub>2</sub>)<sub>n</sub>-heteroaryl, where n is 0, 1 or 2, and where said aryl and said heteroaryl moieties are optionally substituted with one or more substituents;

L is -C(O)- or -C(R<sup>4</sup>)(OR<sup>5</sup>)-, where R<sup>4</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl and R<sup>5</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or taken together with R<sup>6</sup> or R<sup>9</sup> is -CH<sub>2</sub>CH<sub>2</sub>- or -CH<sub>2</sub>C(O)-;


R<sup>6</sup> and R<sup>7</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl, or R<sup>6</sup> and R<sup>7</sup> taken together form a partially or fully saturated carbocyclic ring; and

R<sup>8</sup> and R<sup>9</sup> are each independently hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, -C(O)(CH<sub>2</sub>)<sub>m</sub>R<sup>10</sup>, -SO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>R<sup>10</sup>, or -(CH<sub>2</sub>)<sub>p</sub>R<sup>10</sup>, where m and n are 0, 1, or 2, p is 0, 1, 2 or 3, and R<sup>10</sup> is selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, a partially or fully saturated cycloalkyl, aryl, heteroaryl, and a partially or fully saturated heterocycle, where said (C<sub>1</sub>-C<sub>6</sub>)alkyl, said cycloalkyl, said aryl, said heteroaryl and said heterocycle are optionally substituted with one or more substituents; or

~~R<sup>6</sup> and R<sup>9</sup> taken together form a partially or fully saturated, 4- to 8-membered heterocyclic ring containing 1 to 3 heteroatoms and optionally substituted with one or more substituents;~~

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

2. **(currently amended)** The compound of Claim 1, wherein said compound of Formula (I) is a compound of Formula (IA)



(IA)

wherein

R<sup>1</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>2</sup> and R<sup>3</sup> are each independently -(CH<sub>2</sub>)<sub>n</sub>-aryl or -(CH<sub>2</sub>)<sub>n</sub>-heteroaryl, where n is 0, 1 or 2, and where said aryl and said heteroaryl moieties are each optionally substituted with one to three substituents; and

R<sup>6</sup> and R<sup>7</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl, or R<sup>6</sup> and R<sup>7</sup> taken together form a partially or fully saturated carbocyclic ring; and

~~R<sup>8</sup> and R<sup>9</sup> taken together form a partially or fully saturated, 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms and optionally substituted with one or more substituents;~~

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

3. **(withdrawn)** The compound of Claim 2 selected from the group consisting of

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-piperidin-1-yl-ethanone;

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanone;


1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-[4-(1-methyl-1H-pyrrole-2-carbonyl)-piperazin-1-yl]-ethanone;

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-[4-(1-methyl-cyclopropanecarbonyl)-piperazin-1-yl]-ethanone;

N-(1-[2-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-oxo-ethyl]-piperidin-4-yl)-2,2,2-trifluoro-acetamide;

1-[5-(4-chloro-phenyl)-1-(2-fluoro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanone;  
 1-[5-(4-chloro-phenyl)-1-(2-fluoro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-piperidin-1-yl-ethanone;  
 1-[5-(4-chloro-phenyl)-1-(2-fluoro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(4-trifluoroacetyl-piperazin-1-yl)-ethanone;  
 1-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-pyrrolidin-1-yl-ethanone;  
 1-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-[1,4]oxazepan-4-yl-ethanone; and  
 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(1-oxa-8-aza-spiro[4.5]dec-8-yl)-ethanone;  
 a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

**4. (currently amended)** The compound of Claim 1, wherein said compound of Formula (I) is a compound of Formula (IB)



wherein

$R^1$  is hydrogen or  $(C_1-C_6)$ alkyl;

$R^2$  and  $R^3$  are each independently  $-(CH_2)_n$ -aryl or  $-(CH_2)_n$ -heteroaryl, where n is 0, 1 or 2, and where said aryl and said heteroaryl moieties are each optionally substituted with one to three substituents;

$R^4$  is hydrogen or  $(C_1-C_6)$ alkyl;

$R^5$  is hydrogen or  $(C_1-C_6)$ alkyl;

$R^6$  and  $R^7$  are each independently hydrogen or  $(C_1-C_6)$ alkyl, or  $R^6$  and  $R^7$  taken together form a partially or fully saturated carbocyclic ring; and

$R^8$  and  $R^9$  are each independently hydrogen,  $(C_1-C_6)$ alkyl,

$-\text{C}(\text{O})(\text{CH}_2)_m\text{R}^{10}$ ,  $-\text{SO}_2(\text{CH}_2)_n\text{R}^{10}$ , or  $-(\text{CH}_2)_p\text{R}^{10}$ , where  $m$  and  $n$  are 0, 1, or 2,  $p$  is 0, 1, 2 or 3, and  $\text{R}^{10}$  is selected from the group consisting of  $(\text{C}_1\text{-C}_8)\text{alkyl}$ , a partially or fully saturated cycloalkyl, aryl, heteroaryl, and a partially or fully saturated heterocycle, where said  $(\text{C}_1\text{-C}_8)\text{alkyl}$ , said cycloalkyl, said aryl, said heteroaryl and said heterocycle are optionally substituted with one or more substituents, or

~~$\text{R}^8$  and  $\text{R}^9$  taken together form a partially or fully saturated, 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms and optionally substituted with one or more substituents;~~

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

5. **(withdrawn)** The compound of Claim 4 selected from the group consisting of 2-(benzyl-isopropyl-amino)-1-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-ethanol;

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(3,5-dimethyl-piperidin-1-yl)-ethanol;

1-[2-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-hydroxy-ethyl]-4-isopropylamino-piperidine-4-carboxylic acid amide;


1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(3,3-dimethyl-piperidin-1-yl)-ethanol;

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-piperidin-1-yl-ethanol; and

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanol;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

6. **(withdrawn)** The compound of Claim 1 wherein said compound of Formula (I) is a compound of Formula (IC)



(IC)

wherein

R<sup>1</sup> is hydrogen or (C<sub>1</sub>-C<sub>8</sub>)alkyl;

R<sup>2</sup> and R<sup>3</sup> are each independently -(CH<sub>2</sub>)<sub>n</sub>-aryl or -(CH<sub>2</sub>)<sub>n</sub>-heteroaryl, where n is 0, 1 or 2, and where said aryl and said heteroaryl moieties are each optionally substituted with one to three substituents;

R<sup>6</sup> and R<sup>7</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>8</sub>)alkyl, or R<sup>6</sup> and R<sup>7</sup> taken together form a partially or fully saturated carbocyclic ring; and

R<sup>9</sup> is hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl, -C(O)(CH<sub>2</sub>)<sub>m</sub>R<sup>10</sup>, -SO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>R<sup>10</sup>, or -(CH<sub>2</sub>)<sub>p</sub>R<sup>10</sup>, where m and n are 0, 1, or 2, p is 0, 1, 2 or 3, and R<sup>10</sup> is selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, a partially or fully saturated cycloalkyl, aryl, heteroaryl, and a partially or fully saturated heterocycle, where said (C<sub>1</sub>-C<sub>8</sub>)alkyl, said cycloalkyl, said aryl, said heteroaryl and said heterocycle are optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

7. **(withdrawn)** The compound of Claim 6 selected from the group consisting of 2-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-4-cyclohexyl-morpholine;

2-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-4-(propane-2-sulfonyl)-morpholine;


2-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-4-(toluene-4-sulfonyl)-morpholine;

1-[2-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-morpholin-4-yl]-2-methyl-propan-1-one;

2-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-4-(4-trifluoromethyl-benzyl)-morpholine; and

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

8. **(withdrawn)** The compound of Claim 1, wherein said compound of Formula (I) is a compound of Formula (ID)



(ID)

wherein

R<sup>1</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>2</sup> and R<sup>3</sup> are each independently -(CH<sub>2</sub>)<sub>n</sub>-aryl or -(CH<sub>2</sub>)<sub>n</sub>-heteroaryl, where n is 0, 1 or 2, and where said aryl and said heteroaryl moieties are each optionally substituted with one to three substituents;

R<sup>6</sup> and R<sup>7</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl, or R<sup>6</sup> and R<sup>7</sup> taken together form a partially or fully saturated carbocyclic ring; and

R<sup>8</sup> and R<sup>9</sup> taken together form a partially or fully saturated, 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms and optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

9. **(withdrawn)** The compound of Claim 8 selected from the group consisting of 1-[1-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-methyl-1H-imidazol-4-yl]-2-piperidin-1-yl-ethanone; and

1-[1-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-methyl-1H-imidazol-4-yl]-2-morpholin-4-yl-ethanone;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

10. **(original)** The compound of Claim 1, 2, 4, 6, or 8 wherein R<sup>2</sup> is *p*-chlorophenyl or *p*-fluorophenyl, and R<sup>3</sup> is 2,4-dichlorophenyl, 2-chlorophenyl or 2-fluorophenyl.

11. **(original)** A pharmaceutical composition comprising

(a) a compound of Claim 1, a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt; and

(b) a pharmaceutically acceptable excipient, diluent, or carrier.

12. **(canceled)**

13. **(canceled)**

14. **(withdrawn)** A method for treating a disease, condition or disorder modulated by a cannabinoid receptor antagonist in animals comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a compound of Claim 1, a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

15. **(withdrawn)** The method of Claim 14 wherein said cannabinoid receptor is a CB1 receptor.

16. **(withdrawn)** The method of Claim 15 wherein said disease, condition or disorder modulated by a cannabinoid receptor antagonist is selected from the group consisting of weight loss, obesity, bulimia, depression, atypical depression, bipolar disorders, psychoses, schizophrenia, behavioral addictions, suppression of reward-related behaviors, alcoholism, tobacco abuse, memory loss, Alzheimer's disease, dementia of aging, seizure disorders, epilepsy, attention deficit disorder, Parkinson's disease, gastrointestinal disorders, and type II diabetes.

17. **(withdrawn)** The method of Claim 15 wherein said disease is obesity, bulimia, attention deficit disorder, alcoholism, or tobacco abuse.

18. **(withdrawn)** A method for treating a disease, condition or disorder modulated by a cannabinoid receptor antagonist in animals comprising the step of administering to an animal in need of such treatment two separate pharmaceutical compositions comprising

- (i) a first composition comprising a compound of Claim 1 and a pharmaceutically acceptable excipient, diluent, or carrier, and
- (ii) a second composition comprising at least one additional pharmaceutical agent and a pharmaceutically acceptable excipient, diluent, or carrier.

19. **(withdrawn)** The method of Claim 18 wherein said at least one additional pharmaceutical agent is a nicotine partial agonist, an opioid antagonist, a dopaminergic agent, an attention deficit disorder agent, or an anti-obesity agent.

20. **(withdrawn)** The method of Claim 19 wherein said anti-obesity agent is selected from the group consisting of an apo-B/MTP inhibitor, a 11 $\beta$ -hydroxy steroid dehydrogenase-1 inhibitor, peptide YY<sub>3-36</sub> or an analog thereof, a MCR-4 agonist, a CCK-A agonist, a monoamine reuptake inhibitor, a sympathomimetic agent, a  $\beta_3$  adrenergic receptor agonist, a dopamine agonist, a melanocyte-stimulating hormone receptor analog, a 5-HT<sub>2c</sub> receptor agonist, a melanin concentrating hormone antagonist, leptin, a leptin analog, a leptin receptor agonist, a galanin antagonist, a lipase inhibitor, a bombesin agonist, a neuropeptide-Y receptor antagonist, a thyromimetic agent, dehydroepiandrosterone or analog thereof, a glucocorticoid receptor antagonist, an orexin receptor antagonist, a glucagon-like peptide-1 receptor agonist, a ciliary neurotrophic factor, a human agouti-related protein antagonist, a ghrelin receptor antagonist, a histamine 3 receptor antagonist or inverse agonist, and a neuromedin U receptor agonist.

21. **(withdrawn)** The method of Claim 18 wherein said first composition and said second composition are administered simultaneously.

22. **(withdrawn)** The method of Claim 18 wherein said first composition and said second composition are administered sequentially and in any order.

23. **(withdrawn)** The method of Claim 18, 19, 20, 21, or 22 wherein said disease is obesity, bulimia, attention deficit disorder, alcoholism, or tobacco abuse.



24. **(new)** The compound selected from the group consisting of

2-(Benzyl-isopropyl-amino)-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-ethanone hydrochloride salt;

2-(Benzyl-isopropyl-amino)-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-ethanol;

2-(Benzyl-isopropyl-amino)-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-ethanol hydrochloride;

2-[Benzyl-(2-hydroxy-ethyl)-amino]-1-[5-(4-chlorophenyl)-1-(2-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-ethanol;

1-Benzylamino-1-[5-(4-chlorophenyl)-1-(2-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-ethanol hydrochloride;

benzyl-{2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-methoxy-ethyl}-isopropyl-amine; and

1-(Benzyl-isopropyl-amino)-2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-propan-2-ol;

or a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.